Economic Model For Antibiotics Is Broken, AstraZeneca’s Rex Says
This article was originally published in Pharmaceutical Approvals Monthly
A better economic model for anti-infective research would include incentives to start antibiotic R&D, AstraZeneca exec John Rex tells ICAAC, and go beyond current initiatives that provide financial relief after a new antibiotic is developed.
You may also be interested in...
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
FDA and industry are turning their attention to implementation of the Generating Antibiotic Incentives Now provisions of PDUFA V, which include an additional five years of marketing exclusivity for certain products and new guidance aimed at streamlining the drug development process.
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.